Sandy Allerheiligen, PhD, is Sr Vice President of Strategic Consulting, Health Economics, and Education at Certara. She led their integration of health economics, real world data analytics, and pharmacometrics approaches. Currently, she focuses on leveraging these tools in drug development and teaching and mentoring on Model Based Drug Discovery Development.
Dr Allerheiligen joined Merck in 2010 as Vice President of Modeling and Simulation, and was named Vice President of PPDM: Quantitative Pharmacology & Pharmacometrics in 2013. Her team was instrumental in expanding Model Informed Drug Discovery and Development. In 2016, she became Vice President of Predictive and Economic Modeling and Data Sciences using quantitative approaches to inform discovery to clinical trials to patient access prior to retiring in 2017.
Prior to joining Merck, she held positions at Eli Lilly & Company including Global Senior Director Pharmacokinetics, Pharmacodynamics (PK/PD) & Trial Simulation, Senior Director Drug Disposition, and Distinguished Fellow & Chief Scientific Officer of Quantitative Pharmacology.
Her research focuses on the application of mathematical methods to enable quantitative decisions for nonclinical, clinical development, and patient access. She has applied modeling and simulation approaches to oncolytic and endocrine agents. Her recent work has centered on the integration of experimental and real-world data to enable development of drug disease models to inform decisions through the utilization of quantitative and systems pharmacology, pharmacoeconomic, and other modeling approaches.
Dr. Allerheiligen received her doctorate in Pharmaceutics from the University of Texas, Austin. She completed her postdoctoral fellowship in Gastroenterology and served as a clinical assistant professor of Clinical Pharmacology at The University of Texas Health Science Center at San Antonio.
Through Dr Allerheiligen’s involvement in American Association of Pharmaceutical Scientists, American Association of Clinical Pharmacology and Therapeutics, International Society of Pharmacometrics, and NIH Working Groups, she has worked to expand the use of Modeling and Simulation and Quantitative & Systems Pharmacology methodologies in academia, regulatory agencies, and across the industry. She is a Fellow of the American Association of Pharmaceutical Sciences and the American College of Clinical Pharmacology. She received the 2016 International Society of Pharmacometrics Leadership Award. Dr. Allerheiligen is Adjunct Professor at Monash University, University of Florida College of Pharmacy, and Clinical Pharmacology at University of Indiana Medical School. She frequently lectures on modeling and simulation topics.